Literature DB >> 3305004

Development of resistance during antibiotic therapy.

D Milatovic, I Braveny.   

Abstract

The frequency of development of resistance during antibiotic therapy was evaluated by reviewing the literature according to prescribed criteria. Mean resistance rates were calculated to be 9.2% for broad spectrum penicillins, 8.6% for second and third generation cephalosporins, 10.0% for latamoxef, 4.7% for imipenem, 11.8% for ciprofloxacin and 13.4% for aminoglycosides. Emergence of resistance of the infecting organism was associated with therapeutic failure in about half of the cases with the exception of patients treated with aminoglycosides in whom development of resistance resulted in treatment failure in 85% of the cases. The possible benefit of combination therapy in terms of resistance development is discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3305004     DOI: 10.1007/BF02017607

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  70 in total

1.  Fatal staphylococcal endocarditis treated with erythromycin; rapid development of resistance in vivo and in vitro.

Authors:  R J ROANTREE; L A RANTZ
Journal:  AMA Arch Intern Med       Date:  1955-02

2.  Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.

Authors:  J Guibert; D Destrée; C Konopka; J Acar
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Evaluation of an indanyl ester of carbenicillin.

Authors:  J F Wallace; E Atlas; D M Bear; N K Brown; H Clark; M Turck
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

4.  Piperacillin therapy for serious bacterial infections.

Authors:  D J Winston; W Murphy; L S Young; W L Hewitt
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

5.  Imipenem/cilastatin therapy of bacteremia.

Authors:  L J Eron
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

6.  Ceftazidime in patients with Pseudomonas infections.

Authors:  L J Eron; C H Park; D L Hixon; R I Goldenberg; D M Poretz
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

7.  Ceftriaxone therapy of serious bacterial infections.

Authors:  L J Eron; C H Park; R I Goldenberg; D M Poretz
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

8.  Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections.

Authors:  M J Gribble; A W Chow; S C Naiman; J A Smith; W R Bowie; S L Sacks; L Grossman; N Buskard; G H Growe; L H Plenderleith
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

9.  Ceftriaxone therapy of serious bacterial infections in adults.

Authors:  M J Bittner; D L Dworzack; L C Preheim; R W Tofte; K B Crossley
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

10.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

View more
  45 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 3.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

4.  Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Authors:  Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

5.  Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections.

Authors:  J S Solomkin; E P Dellinger; N V Christou; R W Busuttil
Journal:  Ann Surg       Date:  1990-11       Impact factor: 12.969

6.  [Not Available].

Authors:  A Chaibdraa; M S Medjellekh; A Saouli; M C Bentakouk
Journal:  Ann Burns Fire Disasters       Date:  2008-12-31

7.  The optimal deployment of synergistic antibiotics: a control-theoretic approach.

Authors:  Rafael Peña-Miller; David Lähnemann; Hinrich Schulenburg; Martin Ackermann; Robert Beardmore
Journal:  J R Soc Interface       Date:  2012-05-23       Impact factor: 4.118

8.  Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

Authors:  A L Barry; P C Fuchs; M A Pfaller; S D Allen; E H Gerlach
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

9.  Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Authors:  Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

10.  Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Brian T Tsuji; Craig R Rayner; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.